OmniAb is no longer waiting for the partner book to mature. Two licensed antibodies jumped from early human testing straight into large confirmatory trials during the second quarter, and those stage-gates dropped high-margin milestone cash onto a cost base that barely moved. The equity debate is not whether the transgenic discovery platform can generate candidates. The debate is whether a front-loaded milestone year is the start of a repeating collection cycle or a one-time harvest that fades once the first-half calendar empties.
Johnson and Johnson moved ramantamig, a three-target myeloma antibody, into a head-to-head confirmatory study after a single early-stage trial. Merck KGaA dosed the first patient in a confirmatory colorectal study of precemtabart tocentecan, an antibody-drug conjugate aimed at CEACAM5. Those two jumps, plus a Teva vitiligo program that attracted a large Royalty Pharma funding package, explain why license and milestone fees overwhelmed every other line. Operating costs stayed roughly flat with the year-ago quarter, so almost all of the extra revenue fell through to a narrower loss and a collapse in cash used by operations. That is the leverage the platform thesis always promised. It is also the leverage that disappears if the next two quarters look like the implied second-half guide rather than like the first half.
Guidance now sits above the prior range, yet the new full-year band leaves only a thin remainder after a first half that already captured most of the year. Management has said openly that milestone activity this year is weighted to the opening six months. Royalty receipts are still a rounding error next to license fees, and the instrument business remains too small to carry the print. The question the rest of the year answers is simple: does the thirty-four-program clinical book keep throwing off cash after this burst, or does the collection engine go quiet until the next partner stage-gate?